Indications and Oncologic Outcome of Radical Cystectomy for Urothelial Bladder Cancer †

European Urology, Supplements

Volumn 9, Issue 1, 2010, Pages 10-18

  Gschwend, Juergen E ^a   Retz, Margitta ^a   Kuebler, Hubert ^a   Autenrieth, Michael ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Invasive bladder cancer; Oncological outcome; Radical cystectomy

Indexed keywords

BCG VACCINE;

BLADDER CANCER; CANCER CONTROL; CANCER GROWTH; CANCER INVASION; CYSTECTOMY; DISEASE FREE SURVIVAL; DRUG TREATMENT FAILURE; HUMAN; MEDLINE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURGICAL APPROACH; SURGICAL TECHNIQUE; SURVIVAL RATE; SURVIVAL TIME; TREATMENT INDICATION; TREATMENT OUTCOME; UROGENITAL TRACT CANCER;

EID: 77249176528     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2010.01.004     Document Type: Review

References (67)

1. Tyczynski JE, Parkin DM. ENCR cancer fact sheets: bladder cancer in Europe. European Network of Cancer Registries Web site. http://www.encr.com.fr/bladder-factsheets.pdf. Updated September 2003. Accessed December 2009.
2. Whitmore Jr. W.F. Total cystectomy. In: Cooper E.H., and Williams R.E. (Eds). The biology and clinical management of bladder cancer (1975), Blackwell Scientific Publications, Oxford, UK 193-227
3. Wood D.P., Montie J.E., Maatman T.J., and Beck G.J. Radical cystectomy for carcinoma of the bladder in the elderly patients. J Urol 138 (1987) 46-48
4. Skinner D.G., and Lieskovsky G. Management of invasive and high-grade bladder cancer. In: Skinner D.G., and Lieskovsky G. (Eds). Diagnosis and management of genitourinary cancer (1988), WB Saunders, Philadelphia, PA 295-312
5. Novotny V., Hakenberg O.W., Wiessner D., et al. Perioperative complications of radical cystectomy in a contemporary series. Eur Urol 51 (2007) 397-402 discussion 401-2
6. Hautmann R.E., Gschwend J.E., de Petriconi R.C., Kron M., and Volkmer B.G. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 176 (2006) 486-492
7. Witjes J.A., and Douglass J. The role of hexaminolevulinate fluorescence cystoscopy in bladder cancer. Nat Clin Pract Urol 4 (2007) 542-549
8. Dutta S.C., Smith Jr. J.A., Shappell S.B., Coffey C.S., Chang S.S., and Cookson M.S. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166 (2001) 490-493
9. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162 (1999) 74-76
10. Jakse G., Algaba F., Malmström P.-U., and Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: why?. Eur Urol 45 (2004) 539-546
11. Epstein J.I. The new World Health Organization/International Society of Urological Pathology (WHO/ISUP) classification for TA, T1 bladder tumors: is it an improvement?. Crit Rev Oncol Hematol 47 (2003) 83-89
12. Harnden P. A critical appraisal of the classification of urothelial tumours: time for a review of the evidence and a radical change?. BJU Int 99 (2007) 723-725
13. Burger M., Denzinger S., Wieland W.F., Stief C.G., Hartmann A., and Zaak D. Does the current World Health Organization classification predict the outcome better in patients with noninvasive bladder cancer of early or regular onset?. BJU Int 102 (2008) 194-197
14. Burger M., van der Aa M.N.M., van Oers J.M.M., et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 54 (2008) 835-844
15. Miladi M., Peyromaure M., Zerbib M., Saïghi D., and Debre B. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 43 (2003) 241-245
16. Schwaibold H.E., Sivalingam S., May F., and Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int 97 (2006) 1199-1201
17. Brauers A., Buettner R., and Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?. J Urol 165 (2001) 808-810
18. Soloway M.S., Lee C.T., Steinberg G.D., Ghandi A.A., and Jewett M.A. Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder. Urol Oncol 25 (2007) 338-340
19. Herr H.W., Donat S.M., and Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy?. J Urol 177 (2007) 75-79
20. Chang S.S., Hassan J.M., Cookson M.S., Wells N., and Smith J.A. Delaying radical cystectomy for muscle invasive bladder cancer results in worse pathological stage. J Urol 170 (2003) 1085-1087
21. Hautmann R.E., and Paiss T. Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy?. J Urol 159 (1998) 1845-1850
22. Sanchez-Ortiz R.F., Huang W.C., Mick R., Van Arsdalen K.N., Wein A.J., and Malkowicz S.B. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 169 (2003) 110-115 discussion 115
23. Lee C.T., Madii R., Daignault S., et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J. Urol 175 (2006) 1262-1267 discussion 1267
24. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666-675
25. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 21 (2003) 690-696
26. Dalbagni G., Herr H.W., and Reuter V.E. Impact of a second transurethral resection on the staging of T1 bladder cancer. Urology 60 (2002) 822-824
27. Herr H.W., and Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 166 (2001) 1296-1299
28. Thalmann G.N., Markwalder R., Shahin O., Burkhard F.C., Hochreiter W.W., and Studer U.E. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?. J Urol 172 (2004) 70-75
29. Masood S., Sriprasad S., Palmer J.H., and Mufti G.R. T1G3 bladder cancer-indications for early cystectomy. Int Urol Nephrol 36 (2004) 41-44
30. Bianco Jr. F.J., Justa D., Grignon D.J., Sakr W.A., Pontes J.E., and Wood Jr. D.P. Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy. Urol Oncol 22 (2004) 290-294
31. Lambert E.H., Pierorazio P.M., Olsson C.A., Benson M.C., McKiernan J.M., and Poon S. The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy. BJU Int 100 (2007) 33-36
32. Gupta A., Lotan Y., Bastian P.J., et al. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology 71 (2008) 302-307
33. Denzinger S., Fritsche H.-M., Otto W., Blana A., Wieland W.-F., and Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?. Eur Urol 53 (2008) 146-152
34. Oosterlinck W., Lobel B., Jakse G., Malmström P.-U., and Stöckle M. Sternberg C, The EAU Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 41 (2002) 105-112
35. Pansadoro V., Emiliozzi P., de Paula F., Scarpone P., Pansadoro A., and Sternberg C.N. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin:18-year experience. Urology 59 (2002) 227-231
36. Margel D., Tal R., Golan S., Kedar D., Engelstein D., and Baniel J. Long-term follow-up of patients with stage T1 high-grade transitional cell carcinoma managed by bacille Calmette-Guérin immunotherapy. Urology 69 (2007) 78-82
37. Wiesner C., Pfitzenmaier J., Faldum A., Gillitzer R., Melchior S.W., and Thuroff J.W. Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy. BJU Int 95 (2005) 301-305
38. Nieder A.M., Brausi M., Lamm D., et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 66 (2005) 108-125
39. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
40. Kulkarni G.S., Hakenberg O.W., Gschwend J.E., et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 57 (2010) 60-70
41. Jakse G., Hall R., Bono A., et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol 40 (2001) 144-150
42. Losa A., Hurle R., and Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 163 (2000) 68-71
43. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study. J Urol 163 (2000) 1124-1129
44. de Reijke T.M., Kurth K.H., Sylvester R.J., et al. European Organization for the Research and Treatment of Cancer Genito-Urinary Group. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer Genito-Urinary Group phase III trial (30906). J Urol 173 (2005) 405-409
45. Solsona E., Iborra I., Rubio J., Casanova J., and Almenar S. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour. BJU Int 94 (2004) 1258-1262
46. Hudson M.A., and Herr W.H. Carcinoma in situ of the bladder. J Urol 53 (1995) 564-572
47. Merz V.W., Marth D., Kraft R., Ackermann D.K., Zingg E.J., and Studer U.E. Analysis of early failures after intravesical instillation therapy with bacille Calmette-Guerin for carcinoma in situ of the bladder. Br J Urol 75 (1995) 180-184
48. Shariat S.F., Karakiewicz P.I., Palapattu G.S., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176 (2006) 2414-2422 discussion 2422
49. Gschwend J.E., Dahm P., and Fair W.R. Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. Eur Urol 41 (2002) 440-448
50. Bassi P., Ferrante G.D., Piazza N., et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol 161 (1999) 1494-1497
51. Lerner S.P., Skinner D.G., Lieskovsky G., et al. The rationale for en bloc pelvic lymph node dissection for bladder cancer patients with nodal metastases: long-term results. J Urol 149 (1993) 758-765
52. Melicow M.M., and Hollowell J.W. Intra-urothelial cancer: carcinoma in situ, Bowen's disease of the urinary system: discussion of thirty cases. J Urol 68 (1952) 763-767
53. Pagano F., Bassi P., Ferrante G.L.D., et al. Is stage pT4a (D1) reliable in assessing transitional cell carcinoma involvement of the prostate in patients with a concurrent bladder cancer? A necessary distinction for contiguous or noncontiguous involvement. J Urol 155 (1996) 244-247
54. Esrig D., Freeman J.A., Elmajian D.A., et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol 156 (1996) 1071-1076
55. See W.A., and Fuller J.R. Staging of advanced bladder cancer: current concepts and pitfalls. Urol Clin North Am 19 (1992) 663-683
56. Vieweg J., Withmore Jr. W.R., Herr H.W., et al. The role of pelvic lymphadenectomy and radical cystectomy for lymph node positive bladder cancer. Cancer 73 (1994) 3020-3028
57. Vieweg J., Gschwend J.E., Herr H.W., and Fair W.R. The impact of primary stage on survival in patients with lymph node positive bladder cancer. J Urol 161 (1999) 72-76
58. Vieweg J., Gschwend J.E., Herr H.W., and Fair W.R. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 161 (1999) 449-454
59. Herr H.W., and Donat S.M. Outcome of patients with grossly node positive bladder cancer after pelvic lymph node dissection and radical cystectomy. J Urol 165 (2001) 62-64
60. Pagano F., Bassi P., Galetti T.P., et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J Urol 145 (1991) 45-50
61. Freeman J.A., Esrig D., Stein J.P., et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 76 (1995) 833-839
62. Ok J.H., Meyers F.J., and Evans C.P. Medical and surgical palliative care of patients with urological malignancies. J Urol 174 (2005) 1177-1182
63. Ubrig B., Lazica M., Waldner M., and Roth S. Extraperitoneal bilateral cutaneous ureterostomy with midline stoma for palliation of pelvic cancer. Urology 63 (2004) 973-975
64. Zebic N., Weinknecht S., and Kroepfl D. Radical cystectomy in patients aged ≥75 years: an updated review of patients treated with curative and palliative intent. BJU Int 95 (2005) 1211-1214
65. El-Tabey N.A., Osman Y., Mosbah A., Mohsen T., and Abol-Enein H. Bladder cancer with obstructive uremia: oncologic outcome after definitive surgical management. Urology 66 (2005) 531-535
66. Nagele U., Anastasiadis A.G., Merseburger A.S., et al. The rationale for radical cystectomy as primary therapy for T4 bladder cancer. World J Urol 25 (2007) 401-405
67. Lodde M., Palermo S., Comploj E., et al. Four years experience in bladder preserving management for muscle invasive bladder cancer. Eur Urol 47 (2005) 773-779 discussion 778-9